← Back to Search

Behavioural Intervention

Digital Health Programs for OCD

N/A
Waitlist Available
Led By Sabine Wilhelm, Ph.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Current diagnosis of primary DSM-5 OCD, based on MINI
At least 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up endpoint (week 12)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing two digital health programs for OCD in order to see if they are effective and accessible treatments for the disorder.

Who is the study for?
This trial is for adults in the U.S. with a primary diagnosis of OCD, stable on any psychotropic meds for at least 2 months. It's not suitable for those with recent CBT treatment or app use for OCD, severe depression or substance issues, bipolar disorder, psychosis, acute suicidal thoughts, PTSD, or who are receiving other psychological treatments.
What is being tested?
The study compares two digital health programs: Perspectives OCD and The Health and Well-Being Program to see if they can help people manage their OCD symptoms effectively by increasing access to treatment through technology.
What are the potential side effects?
Since this trial involves digital interventions rather than medication, side effects may include discomfort from regular device use such as eye strain or headaches. Emotional distress could also occur due to confronting challenging content related to managing OCD.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with OCD according to the DSM-5 criteria.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~endpoint (week 12)
This trial's timeline: 3 weeks for screening, Varies for treatment, and endpoint (week 12) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Difference in OCD severity (YBOCS) at the end of Week 12
Secondary study objectives
Difference in depression at the end of Week 12
Difference in functional impairment at the end of Week 12
Difference in quality of life at the end of Week 12

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Perspectives OCDExperimental Treatment1 Intervention
12 week Smartphone-delivered CBT for OCD.
Group II: The Health and Well-Being ProgramActive Control1 Intervention
12 week health and well-being education

Find a Location

Who is running the clinical trial?

Koa Health B.V.Industry Sponsor
5 Previous Clinical Trials
300 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
3,014 Previous Clinical Trials
13,309,211 Total Patients Enrolled
26 Trials studying Obsessive-Compulsive Disorder
1,512 Patients Enrolled for Obsessive-Compulsive Disorder
Sabine Wilhelm, Ph.D.Principal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
230 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
87 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Perspectives OCD (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04136626 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Perspectives OCD, The Health and Well-Being Program
Obsessive-Compulsive Disorder Clinical Trial 2023: Perspectives OCD Highlights & Side Effects. Trial Name: NCT04136626 — N/A
Perspectives OCD (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04136626 — N/A
~28 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top